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Background: Surgical or medical castration and antiestro-
genic treatment with tamoxifen are common endocrine
treatments for premenopausal women with breast cancer.
However, tamoxifen therapy induces high levels of plasma
estradiol, with unknown long-term effects. In this study, we
investigated the effect of combining estrogen suppression
with the luteinizing hormone-releasing hormone agonist
buserelin and estradiol receptor blockade with tamoxifen to
determine whether the high estradiol levels induced by
tamoxifen could be reduced and whether the antitumor ef-
fects would be better. Methods: In a three-arm, randomized,
prospective trial, from 1988 through 1995, a total of 161
premenopausal patients with advanced breast cancer were
randomly assigned to treatment with buserelin, tamoxifen,
or both. Patients with steroid receptor-negative tumors or
with tumors of unknown receptor status who had a disease-
free interval of less than 2 years were excluded. The median
follow-up was 7.3 years, during which 76% of the patients
died, all of breast cancer. Patient and tumor characteristics
were well balanced among treatment groups. All P values
are from two-sided tests. Results: Combined treatment with
buserelin and tamoxifen was superior to treatment with
buserelin or tamoxifen alone by objective response rate
(48%, 34%, and 28% of patients who could be evaluated,
respectively; P = .11 [x2 test]), median progression-free sur-
vival (9.7 months, 6.3 months, and 5.6 months; P = .03), and
overall survival (3.7 years, 2.5 years, and 2.9 years; P = .01).
Actuarial 5-year survival percentages were 34.2% (95% con-
fidence interval [CI] = 20.4%–48.0%), 14.9% (95% CI =
3.9%–25.9%), and 18.4% (95% CI = 7.0%–29.8%), respec-
tively. No differences in antitumor effects were observed be-
tween single-agent treatment groups. During combined
treatment or treatment with buserelin alone, plasma estra-
diol levels were suppressed equally; in contrast, during treat-
ment with tamoxifen alone, plasma estradiol levels increased
threefold to fourfold over pretreatment levels. Conclusion:
Combined treatment with buserelin and tamoxifen was more
effective and resulted in longer overall survival than treat-
ment with either drug alone. [J Natl Cancer Inst 2000;92:
903–11]
Many steroid and peptide hormones, growth factors, and
other trophic substances are involved in the growth regulation of
breast cancer (1–4). Endocrine treatment of breast cancer is de-
signed to decrease plasma concentrations of one or more of these
hormones and growth factors or to inhibit the biologic effects of
these trophic substances directly in the tumor cell. Deprivation
or antagonism of estradiol, a growth-stimulating hormone for
estrogen-dependent breast cancers, is especially important. En-
docrine therapy for breast cancer consists of a variety of medical
and surgical ablative treatments (2,5–10). For premenopausal
patients with metastatic breast cancer, the classic treatment is
ovariectomy (11). After DeSombre et al. (12) showed that a
luteinizing hormone-releasing hormone (LHRH) analogue could
induce tumor regression in an experimental tumor model system,
the results of the first clinical study with an LHRH analogue
were reported by Klijn and de Jong (13). Since then, a series of
more than 13 phase II studies with various LHRH agonists, such
as goserelin, buserelin, and others, have shown an objective
response in 161 (38%) of 419 patients (14). Overall, the objec-
tive response rate in estrogen receptor-positive tumors was 50%.
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Although direct antitumor effects of LHRH analogues have been
demonstrated in vitro and specific LHRH-binding sites have
been found in 52%–67% of primary human breast cancers [for
review, see (15)], the main mechanism of action of LHRH ana-
logues is medical castration. The application of depot formula-
tions (long-acting subcutaneous or intramuscular implants) of
various LHRH agonists caused long-term suppression of ovarian
estrogen secretion (14,16–18). A recent randomized study of
138 premenopausal patients with estrogen receptor-positive and
progesterone receptor-positive metastatic breast cancer (19)
showed that treatment with the LHRH agonist goserelin resulted
in failure-free survival and overall survival similar to those ob-
served after ovariectomy.
Tamoxifen is now the standard first-line therapy for post-
menopausal metastatic breast cancer and is also accepted as an
alternative to ovariectomy in premenopausal patients (5–10).
Based on eight phase II and two phase III clinical studies
involving a total of 348 premenopausal patients treated with
tamoxifen (5), an objective response was observed in 103 pa-
tients (30%). However, the group of premenopausal women
treated with tamoxifen had very high levels of plasma estradiol,
sometimes for many years, because of the tamoxifen-induced
stimulation of pituitary–ovarian functions (2,5,9,20,21). The
possible deleterious effects of these high levels of plasma estra-
diol, which can compete with tamoxifen for binding to estrogen
receptors, have been debated for many years (20). Furthermore,
only two relatively small studies (22,23) have compared the
effectiveness of surgical castration with that of tamoxifen and
showed no major differences in results. However, no definite
conclusions can be reached from these studies [(22,23), but see
also (5,9,19)] because the power of each was very low. In con-
trast, for hormone-dependent breast cancer cells, in vitro studies
(24) have shown that long-term withdrawal of estrogens in-
creased the sensitivity of these cells to estradiol, suggesting that
the addition of an antiestrogen might be valuable.
Combined treatment with LHRH analogues and other endo-
crine agents, such as tamoxifen, therefore, is of great interest
(2,25–29). Endocrine studies (2,26–29) showed that an LHRH
agonist given subcutaneously completely suppressed the tamoxi-
fen stimulation of pituitary and ovarian functions and resulted in
plasma estrogen levels that were comparable to normal post-
menopausal levels. Thus, combination treatment with an LHRH
agonist and tamoxifen can induce a so-called “complete estrogen
blockade,” which is the suppression of plasma estradiol levels by
the LHRH agonist and blockade of the estrogen receptor by the
antiestrogen. Previously, Klijn and Foekens (26) and Nicholson
et al. (29) reported, in small nonrandomized studies, that a com-
bined treatment of buserelin or goserelin with an antisteroidal
agent increased the duration of response.
To test the hypothesis further, we designed a three-arm study
to assess the antitumor and endocrine effects of long-term first-
line combined endocrine treatment with buserelin (an LHRH
agonist) and tamoxifen compared with treatment with each drug
alone. To our knowledge, this study is the only three-arm, ran-
domized study to investigate these treatments for metastatic
breast cancer in premenopausal women.
PATIENTS AND METHODS
Patients and Treatment
During the period from 1988 through 1995, a total of 161 patients were
recruited by 17 centers from nine countries. The patients were premenopausal
and had metastatic or locally advanced breast cancer. They were equally and
randomly assigned to one of three treatment groups according to European
Organization for Research and Treatment of Cancer (EORTC) protocol 10881
approved by the Protocol Review Committee of the EORTC (Table 1). Strati-
fication factors for the randomization included centers, receptor status, disease-
free interval, and stage of disease (metastatic or locally advanced). All patients
entered in this study were informed of the investigational nature of the study
and provided informed consent in accordance with institutional guidelines.
A premenopausal woman was defined as a woman who had a menstrual period
less than 3 months before randomization. All patients had histologically proved
breast cancer with at least one measurable lesion or a lesion that could be
evaluated at the start of treatment. Eligibility criteria also included a posi-
tive estrogen receptor and/or progesterone receptor status (ø10 fmol/mg
of protein), irrespective of the duration of the disease-free interval, or an un-
known steroid receptor status and a disease-free interval of at least 2 years or
longer.
The following patients were excluded from the study: those with tumors that
were both estrogen receptor negative and progesterone receptor negative, those
with a poor performance status (World Health Organization [WHO] status of
>3), those with rapidly progressing life-threatening disease (including extensive
liver metastases, carcinomatous lymphangitic disease of the lungs, or central
nervous system metastases), those with increased concentrations of plasma bil-
irubin (>30 mmol/L) or creatinine (>150 mmol/L), those with other concurrent or
past malignancies (with the exception of adequately treated basal or squamous
cell cancer of the skin and in situ carcinoma of the cervix), and those who were
pregnant. Patients with previous systemic endocrine or chemotherapeutic treat-
ment for advanced disease were not eligible. However, patients with previous
adjuvant treatment with tamoxifen and/or chemotherapy were allowed if they
had received no adjuvant chemotherapy for at least 6 months, if they had re-
ceived no treatment with tamoxifen for more than 1 year before entry, and if
amenorrhea had not occurred. Patients were randomly assigned by the EORTC
Data Center to receive one of three first-line treatments (Table 1). These treat-
ments were 1) buserelin implants (6.6 mg implanted subcutaneously every 8
weeks; during the first 12 weeks, every 6 weeks), 2) a daily dose of tamoxifen
(40 mg administered orally), or 3) a combination of both drugs at the same
dosages. When disease progression was detected, a crossover of drugs (tamoxi-
fen after buserelin or buserelin after tamoxifen) in the single-treatment arms was
advised but was not mandatory. Second-line treatment was left to the discretion
of the local investigator in view of the highly heterogeneous conditions of
individual patients during the course of metastatic disease, which required in-
dividually designed treatments. However, to be informed about the course of the
disease from the time of tumor progression, survival curves from time to failure
of first-line treatment were constructed.
Methods and Follow-up
Patients were clinically evaluated every 6 weeks for the first 12 weeks and
every 8 weeks thereafter until disease progression. At each visit, all complaints,
vaginal bleeding, hot flashes, and other side effects were recorded, in addition to
medications taken and performance status. At each visit, a physical examination,
measurement of palpable lesions, and limited blood tests (alkaline phosphatase
Table 1. Patient population and study design: European Organization for




No. of patients registered 161
No. of patients randomly assigned
to treatment group
161 54 54 53
No. of patients ineligible and/or
not assessable
16 7 4 5
No. of patients assessable for
response
145 47 50 48
Median follow-up, y 7.3
No. of patients with DP 149 49 51 49
No. of deceased patients 122 43 44 35
*LHRH-A 4 buserelin, a luteinizing hormone-releasing hormone agonist;
TAM 4 tamoxifen; DP 4 disease progression during treatment irrespective of
type of response.
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and g-glutamyltransferase) were also carried out. Complete routine hematology
and blood chemistry were done every 16 weeks. Objective clinical assessment
included specific x-rays, computed tomography scans of liver lesions, and pho-
tographs of skin metastasis every 8–16 weeks, as appropriate, and bone scans
every 6 months. In nearly all centers, plasma estradiol levels were measured
every 6–8 weeks during the first year and every 16 weeks thereafter by institu-
tional standard assays. Values below the detection level of the respective estra-
diol assays were given the limiting value of the assay. Between centers, the upper
levels of normal postmenopausal plasma concentrations varied from 19 pg/mL to
38 pg/mL. For a patient treated longer than 1 year and who had more than one
plasma estradiol determination per year, the average estradiol value per year for
that patient was used. Steroid receptor determinations were performed by a
ligand-binding assay according to guidelines of the EORTC Biomarker Study
Group (30), by enzyme immunoassays (31), or infrequently by immunohisto-
chemistry. Response to treatment was assessed by use of standard criteria of the
International Union Against Cancer (32). For patients with bone metastases and
a complete response, complete remineralization of lytic lesions in the bone was
required, or, for a partial response, a clear improvement accompanied by a
decrease in pain was required. Bisphosphonates were not used in this study. The
Data Center and the study coordinator reviewed all forms.
Statistical Analysis
The study was designed to compare the objective response rate of the com-
bined treatment with the objective response rate of the single-drug arms and to
detect an increase from 40% to 60% in this rate. Therefore, the aim was to accrue
116 patients in each arm to reach a power of 80% for a two-sided test with an
a value of .05. Accrual to the study was slower than expected and, because of
the decreasing accrual and the rapidly increasing application and duration of
systemic adjuvant therapy, the EORTC Breast Cancer Cooperative Group de-
cided to terminate the study prematurely after 7 years.
In our analysis of the three treatment arms, we compared two time-to-event
end points, progression-free survival and overall survival, as well as one ordered
categorical end point, objective response rate, which consisted of four categories
(i.e., complete remission, partial remission, no change, and progressive disease).
For the time-to-event end points, an overall test for the difference among the
three treatment groups was based on the log-rank test (33) of data from all
patients (intent-to-treat principle). The three treatment arms were also compared
pairwise by the log-rank test. With the use of an overall statistical significance
level of 5%, each pairwise comparison was tested at the 2% level according to
Tukey’s multiple comparisons method (34). Survival curves for the three treat-
ment groups were estimated by the Kaplan–Meier technique (35). In addition,
stratified analyses were done for the time-to-event end points, based on the Cox
proportional hazards model (36) with the use of patient characteristics for which
there appeared to be an imbalance as stratification factors (e.g., WHO perfor-
mance status). If the stratified and unstratified analyses led to similar results,
results of the more simple unstratified analysis are shown.
Furthermore, the effect of four prognostic factors—i.e., disease-free interval
(<2 years or ø2 years), age (ł40 years or >40 years), dominant site of disease
(soft tissue, bone, or visceral), and adjuvant chemotherapy (yes or no)—on
progression-free survival was studied and tested by the log-rank test. For the
prognostic factors that statistically significantly influenced progression-free sur-
vival, a Cox proportional hazards model was fitted with and without the inter-
action between the treatment and the prognostic factor. A test for interaction
used the likelihood ratio test to compare these two models (37).
The test for the objective response rate was based on the Kruskal–Wallis test
(38). All patients who could be evaluated for response were used. In addition, the
four categories were combined into two categories—i.e., responders (containing
the categories complete remission and partial remission) and nonresponders
(containing the categories no change and progressive disease)—and a x2 test was
done on this binary variable (39). The three treatment arms were also compared
pairwise by the x2 test. Again, each pairwise comparison was tested at the
statistical significance level of .02. A separate but similar analysis was per-
formed after adding data from patients who had had stable disease for more than
6 months to the objective response category (complete remission, partial remis-
sion, and no change for >6 months). The same four prognostic factors were
studied for the binary response variable and were tested with a x2 test. If a
statistically significant effect was obtained, a logistic regression model with and
without the interaction term was fitted, and the two models were again compared
by the likelihood ratio test corresponding to a test for interaction. All P values
are from two-sided tests.
RESULTS
Patient and Tumor Characteristics
During the period from 1988 through 1995, a total of 161
patients were recruited by 17 centers from nine countries as
follows: 64 patients from The Netherlands, 39 from France, 23
from Belgium, 16 from South Africa, eight from Poland, six
from Spain, three from Austria, one from Germany, and one
from Hungary. Nine patients were ineligible and were not evalu-
ated, and seven additional eligible patients could not be evalu-
ated. These 16 patients could not be evaluated because of miss-
ing information (eight patients) or protocol violations (eight
patients). The protocol violations included incorrect receptor sta-
tus (three patients), postmenopausal status (one patient), neoad-
juvant chemotherapy (one patient), brain metastasis (one pa-
tient), treatment refusal (one patient), and early termination of
tamoxifen after 3 days because of hot flashes (one patient). Thus,
data from 145 patients could be evaluated for response (Table 1).
The median follow-up of all 161 patients was 7.3 years. In total,
149 patients showed disease progression and 122 (76%) of the
161 patients died, all of breast cancer. The patient and tumor
characteristics were well balanced over the three treatment
groups (Table 2). A statistically significant difference was ob-
served only for performance status, showing a slightly more
favorable distribution in the group treated with tamoxifen. In
addition, there was a trend to less visceral disease in the group
treated with buserelin alone.
Antitumor Efficacy and Survival
Excluding patients who could not be evaluated, the objective
response rate (complete remission and partial remission) was
better in the group treated with the combination therapy (23
of 48 patients; 48%) than in the groups treated with buserelin
alone (16 of 47 patients; 34%) or tamoxifen alone (14 of 50
patients; 28%) (Table 3). Taking all four types of response into
account, there was a statistically significant difference in the
objective response between the three treatment groups by the
Kruskal–Wallis test (P 4 .031). If the four categories of
response were combined into two categories (complete remis-
sion and partial remission versus no change and progressive
disease), the difference in the response rate between the three
treatment groups was not statistically significant (x2 test; P 4
.11). When we include the data from the 16 patients who could
not be evaluated in the second category (no change and progres-
sive disease), the same P values (both P 4 .13) resulted. How-
ever, when data from patients with stable disease for more than
6 months were added to the objective response category (com-
plete remission, partial remission, and no change for >6 months),
the objective response rate was statistically significantly better
(P 4 .007) in the group with combination therapy (36 of 48
patients; 75%) than in the groups treated with buserelin alone
(29 of 47 patients; 62%) or tamoxifen alone (22 of 50 patients;
44%).
Compared with patients in the combined-treatment arm, pa-
tients treated with buserelin alone or tamoxifen alone had a
lower chance of having an objective response (complete remis-
sion and partial remission; odds ratios of 0.56 and 0.42, respec-
tively). Response rates in patients in the single-treatment arms
compared with those in the combined-treatment arm were dif-
ferent and led to unadjusted P values of .169 for buserelin and
.042 for tamoxifen. In contrast, the response rates in patients
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treated with buserelin alone and in patients treated with tamoxi-
fen alone were much more similar (P 4 .52).
The three treatment arms differed statistically significantly
from each other with regard to progression-free survival (Table
3), with the median times to disease progression being 9.7
months for patients in the combined-treatment group, 6.3
months for patients treated with buserelin alone, and 5.6 months
for patients treated with tamoxifen alone (P 4 .03; overall log-
rank test) (Fig. 1). Presently, the longest duration of response
and the longest duration of administration of combined treat-
ment are more than 11 years. Compared with patients in the
combined-treatment arm, patients treated with buserelin or
tamoxifen alone showed poor progression-free survival, with
hazard ratios of 1.65 (95% confidence interval [CI] 4 1.09–
2.49) and 1.50 (95% CI 4 1.01–2.24), respectively (Table 3).
Separate comparisons of the single-treatment arms to the com-
bined-treatment arm showed differences in progression-free sur-
vival for both single-treatment arms and led to unadjusted P
values of .008 for buserelin and .047 for tamoxifen. Progression-
free survival values for patients treated with buserelin alone and
for patients treated with tamoxifen alone were very similar (P 4
.71).
Thirty-five (66%) of the 53 patients in the combined-
treatment group died, 43 (80%) of the 54 patients in the group
treated with buserelin alone died, and 44 (81%) of the 54
patients in the group treated with tamoxifen alone died. The
overall log-rank test for overall survival showed that these
values were statistically significantly different (P 4 .01) (Fig.
2). Separate comparisons of overall survival among patients
in the single-treatment arms and in the combined-treatment
arm showed that these values were statistically significantly
different, with unadjusted P values of .006 for buserelin and
.029 for tamoxifen. Overall survival values in the groups treated
with buserelin alone and tamoxifen alone were again similar
(P 4 .33). The median overall survival was longer in patients
after combined treatment (3.7 years) than in patients after treat-
ment with buserelin alone (2.5 years) or tamoxifen alone (2.9
years) (P 4 .01) (Table 3). The death hazard ratios for patients
treated with buserelin alone or tamoxifen alone were 1.95 (95%
CI 4 1.23–3.10) and 1.63 (95% CI 4 1.03–2.59), respectively,
when compared with patients receiving the combined treat-
ment. The 5-year actuarial survival was higher for patients in










Median 43 42 43
Range 28–58 24–51 31–50
Weight, kg
Median 64 60 61
Range 45–89 46–90 43–84
World Health Organization
performance status, No. (%)
0 24 (53) 37 (79) 31 (61)
1 16 (36) 10 (21) 14 (27)
2 5 (11) 0 (0) 5 (10)
3 0 (0) 0 (0) 1 (2)
Disease stage, No. (%)
Locally advanced 1 (2) 3 (6) 0 (0)
Metastases 49 (98) 50 (94) 51 (100)
Disease-free interval, No. (%)
<2 y 18 (36) 21 (40) 20 (38)
ø2 y 32 (64) 32 (60) 32 (62)
Surgery, No. (%)
Yes 43 (86) 49 (92) 46 (88)
No 7 (14) 4 (8) 6 (12)
Adjuvant tamoxifen, No. (%)
Yes 3 (6) 0 (0) 1 (2)
No 47 (94) 53 (100) 51 (98)
Adjuvant chemotherapy, No. (%)
Yes 18 (36) 16 (30) 15 (29)
No 32 (64) 37 (70) 37 (71)
Dominant site, No. (%)
Soft tissue 10 (21) 8 (15) 8 (16)
Bone 24 (50) 19 (37) 22 (43)
Visceral 14 (29) 25 (48) 21 (41)
Receptor status
ER- and/or PgR-positive 35 (65) 40 (74) 40 (75)
Unknown 18 (33) 14 (26) 13 (25)
ER- and PgR-negative 1 (2) — (—) — (—)
*Because of missing data, the patient numbers with respect to different char-
acteristics do not always add up to the same total number of patients. LHRH-A
4 luteinizing hormone-releasing hormone agonist (i.e., buserelin); ER 4 es-
trogen receptor; PgR 4 progesterone receptor.












versus combinedNo. % No. % No. %
Complete remission (CR) 2 4 2 4 3 6
Partial remission (PR) 14 30 12 24 20 42
No change (NC) 17 36 13 26 15 31 0.56 (0.24–1.30) 0.42 (0.17–1.06)
Progressive disease 14 30 23 46 10 21
Could not be evaluated 7 4 5
CR + PR + NC > 6 mo 29/47 62 22/50 44 36/48 75
Median progression-free survival
(95% confidence interval)
6.3 mo (4.7–8.3) 5.6 mo (4.5–8.5) 9.7 mo (7.8–14) 1.65 (1.09–2.49) 1.50 (1.01–2.24)
Median overall survival
(95% confidence interval)
2.5 y (1.7–3.5) 2.9 y (2.2–3.8) 3.7 y (2.5–4.8) 1.95 (1.23–3.10) 1.63 (1.03–2.59)
Actuarial survival at 5 y 14.9% 18.4% 34.2%
Actuarial survival at 7 y 5% 10% 30%
*LHRH-A 4 luteinizing hormone-releasing hormone agonist (i.e., buserelin); TAM 4 tamoxifen. NC > 6 months 4 stable disease > 6 months.
†OR 4 odds ratio of having objective response (complete remission + partial remission versus no change + progressive disease); HR 4 hazard ratio for
progression-free and overall survival (with 95% confidence intervals in parentheses).
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the combined-treatment group (34.2%; 95% CI 4 20.4%–
48.0%), with a difference of 15.8%–19.3% in comparison to that
for patients treated with buserelin alone (14.9%; 95% CI 4
3.9%–25.9%) or tamoxifen alone (18.4%; 95% CI 4 7.0%–
29.8%) (Table 3).
Even when additional stratified log-rank tests were done, be-
cause of a slight imbalance in performance status (in favor of the
tamoxifen treatment group), the results and conclusions did not
change, indicating that the combined treatment was always bet-
ter than the single-drug treatments.
For survival after disease progression, there was a border-
line statistically significant difference among the three treat-
ment arms (P 4 .06), with the median time to death from
disease progression being 29 months for patients in the com-
bined-treatment group, 18.3 months for patients
treated with buserelin alone, and 27.1 months
for patients treated with tamoxifen alone (Fig. 3).
Compared with patients receiving combined treat-
ment, patients treated with buserelin alone or
tamoxifen alone showed hazard ratios of 1.7–
1.45 for survival after disease progression. For
survival after disease progression, comparison of
the single-treatment arms with the combined-
treatment arm showed differences, with unadjusted
P values of .03 for buserelin alone and .088 for
tamoxifen alone. Survival values for the group
treated with buserelin alone and for the group
treated with tamoxifen alone were very similar
(P 4 .41).
Prognostic Factors
The disease-free interval was the only prognos-
tic factor that had a statistically significant effect
on progression-free survival (P 4 .011) and over-
all survival (P 4 .02). Patients with a disease-free
interval of 2 years or longer had a median time to
disease progression of 8.3 months, and patients
with a disease-free interval of less than 2 years had
a median time to disease progression of 6.4
months. The median time to death was 39.9
months for patients with a disease-free interval of
2 or more years; it was 32 months for patients with
a disease-free interval of less than 2 years. The
interaction between treatment and disease-free in-
terval, however, was not statistically significant for
progression-free survival (P 4 .43) and overall
survival (P 4 .93).
The dominant site of disease was the only prog-
nostic factor that had a statistically significant ef-
fect on the objective response rate (P 4 .021). The
objective response rate was 59% for patients with
soft-tissue disease, 27% for patients with bone me-
tastases, and 39% for patients with visceral metas-
tases. The interaction between treatment and dom-
inant site, however, was not statistically significant
(P 4 .078), although this interaction test is not
powerful and is based on a restricted number of
patients in each subgroup.
Endocrine Effects on Plasma Estradiol Levels
and Menstrual Cycle and Side Effects
All patients with at least one estradiol measure-
ment result before and/or during treatment were included in the
endocrine study. Because of missing data and the decreasing
number of patients without progressive disease, the number of
patients evaluated decreased during follow-up (Table 4). In the
two groups of patients treated with buserelin alone or buserelin
with tamoxifen, both the median and the mean levels of plasma
estradiol dropped to normal postmenopausal values within 6
weeks and remained suppressed throughout treatment in all pa-
tients (Table 4 and Fig. 4). In the group treated with tamoxifen
alone, however, plasma estradiol levels increased on average
threefold to fourfold in nearly all patients. In the same patients,
this increase fluctuated widely during treatment but persisted for
years throughout treatment with values of 1000 pg/mL or more
(Table 4).
Fig. 1. Progression-free survival of all 161 patients. O 4 number of observed events; N 4
number of patients randomly assigned. LHRH-A 4 luteinizing hormone-releasing hormone
agonist (i.e., buserelin); TAM 4 tamoxifen. P value is from a two-sided test. For more data, see
Table 3.
Fig. 2. Overall survival of all 161 patients. O 4 number of observed events; N 4 number of
patients randomly assigned. LHRH-A 4 luteinizing hormone-releasing hormone agonist (i.e.,
buserelin); TAM 4 tamoxifen. P value is from a two-sided test. For more data, see Table 3.
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Some patients could not be evaluated for amenorrhea and/or
hot flashes because of a short period of treatment caused by early
progressive disease, a prior hysterectomy without ovariectomy,
or missing data. Hot flashes occurred less frequently (P<.001)
during treatment with tamoxifen alone (17 of 43 patients; 40%)
than during treatment with buserelin alone (38 of 43 patients;
88%) or during the combination treatment (41 of 47 patients;
87%). Amenorrhea also developed less often (P<.001) during
treatment with tamoxifen (nine of 38 patients; 24%) than during
treatment with buserelin alone (39 of 40 patients; 98%) or com-
bined treatment (44 of 44 patients; 100%). Nausea was reported
by five patients (three with WHO grade 1 and two with WHO
grade 2; 12%) treated with tamoxifen alone, one patient (grade
1) receiving combined treatment, and no patients treated with
buserelin alone. Nausea in the group treated
with tamoxifen alone might have been partly
related to the high plasma levels of estradiol
that were comparable to those observed during
pregnancy. Three patients in the group treated
with tamoxifen alone experienced abdominal
pain and discomfort caused by ovarian cysts
(one underwent ovariectomy for that reason),
one reported menometrorrhagia, and one re-
ported visual disturbances. No endometrial
carcinoma was reported. Overall, only two
(1.2%) of 161 patients, both (i.e., two [3.7%]
of 54) treated with tamoxifen alone, stopped
treatment because of side effects (severe hot
flashes).
DISCUSSION
Surgical ovariectomy has been used for the
last 100 years as treatment for advanced breast
cancer in premenopausal patients (11). Phase
II studies of medical treatment with tamoxifen
(5) or LHRH agonists (14) showed response
rates that were similar to those observed after
surgical castration. Two randomized studies comparing surgical
ovariectomy with tamoxifen (22,23) and two other randomized
studies comparing surgical ovariectomy with the LHRH agonist
goserelin (19,40) have been reported. Those studies showed that
medical treatment and surgical ablation are equally effective.
Therefore, it was not surprising that, in our three-arm random-
ized study, we did not find statistically significant differences in
any of the three end points tested between groups treated with
tamoxifen alone or buserelin alone. However, most reported
randomized studies had a relatively low power. Therefore, the
possibility of minor differences cannot be excluded. To detect
such small differences, very large studies are required.
From an endocrine point of view, treatment with tamoxifen
and buserelin resulted in important differences. Patients treated
Table 4. Plasma estradiol concentrations (pg/mL) before and during treatment*
Treatment
Follow-up
Baseline 6 wk 12 wk 20 wk 28 wk 36–44 wk 1 y 2 y 3 y 4 y 5–9 y
LHRH-A
Median, pg/mL 114 20 20 11 15 16 22 7 9
Mean, pg/mL 123 23 23 21 21 20 21 19 9
No. of patients 37 30 32 27 19 15 9 3 1
Range, pg/mL
Lowest value 5 4 5 5 8 5 8 6
Highest value 316 109 79 91 54 42 <38 45
TAM
Median, pg/mL 80 256 212 482 346 439 390 208 231 923
Mean, pg/mL 123 425 451 481 339 537 338 149 245 923
No. of patients 32 31 21 13 14 10 10 5 3 2
Range, pg/mL
Lowest value 4 5 33 5 65 35 8 8 131 269
Highest value 544 1523 1632 1034 890 1438 653 269 374 1578
LHRH-A + TAM
Median, pg/mL 68 19 15 16 16 17 15 20 12 17 10
Mean, pg/mL 116 23 18 19 18 18 19 18 13 17 10
No. of patients 34 29 30 25 24 18 17 9 5 4 2
Range, pg/mL
Lowest value 17 5 5 5 5 7 8 8 8 8 8
Highest value 750 107 63 71 56 42 49 34 24 26 11
*LHRH-A 4 luteinizing hormone-releasing hormone (i.e., buserelin); TAM 4 tamoxifen.
Fig. 3. Survival from detection of disease progression of all 161 patients from time to failure of
first-line treatment. O 4 number of observed events; N 4 number of patients randomly assigned.
LHRH-A 4 luteinizing hormone-releasing hormone agonist (i.e., buserelin); TAM 4 tamoxifen. P
value is from a two-sided test. For more data, see Table 3.
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with tamoxifen alone had levels of plasma estradiol that
were threefold to fourfold higher than pretreatment values, and
the elevated levels persisted for several years. In contrast,
patients treated with buserelin alone had postmenopausal
levels of estradiol. Plasma estradiol levels induced by treatment
with buserelin alone were similar to those reported for (short-
term) treatment with goserelin [i.e., mean values of 20–23 pg/
mL (19,28)]. Our combined-treatment regimen of buserelin
and tamoxifen completely suppressed the tamoxifen-stimulated
pituitary–ovarian axis and resulted in plasma estrogen levels
that were similar to those observed during treatment with
buserelin alone. In our trial, progression-free survival (P 4 .03)
and overall survival (P 4 .01) in the group receiving combined
treatment were statistically significantly superior to those in
the groups receiving single-drug treatment (Figs. 1 and 2). Com-
bined treatment also had a 14%–20% higher objective response
rate, although the difference in response rate was not statistically
significant (P 4 .11; Table 3). However, when disease that
was stable for more than 6 months was included in the objec-
tive response category, the differences in clinical benefit in
terms of response rate were highly statistically significant (P 4
.007).
Thus far, only two randomized studies (40,41) that compared
a combined treatment (LHRH agonist and tamoxifen) and treat-
ment with a single LHRH agonist (goserelin) have been re-
ported, and one study in Japan is ongoing. However, none of
these three studies included a third arm with tamoxifen alone.
An arm for treatment with tamoxifen alone is desirable from a
scientific point of view because it can be used to prove that the
benefit of combined treatment is not simply caused by tamoxi-
fen. A small Italian study (40) of 85 patients that had a two-
by-two factorial study design and 18–24 patients per treat-
ment group demonstrated a higher response rate in patients
treated with goserelin plus tamoxifen (45%) than in patients
treated with goserelin alone (27%). Although this difference of
18% is comparable to the results of our study, it was not statis-
tically significant because of the low number of patients in the
study. In addition, no differences with respect to survival and the
results of surgical castration were observed. A second, larger
international study (41) of 318 patients showed, in concordance
with our study, a statistically significantly improved progres-
sion-free survival after combined treatment compared with that
after a single treatment with goserelin (P 4 .03) but no statis-
tically significant improvement in the survival or objective re-
sponse rate (38% versus 31%). However, patients with estrogen
receptor-negative tumors or an unknown estrogen receptor sta-
tus, irrespective of the length of the disease-free interval, were
also included in this study, which “diluted” the patient popula-
tion with patients who had hormone-resistant breast cancer.
However, within the subgroup of 115 patients with skeletal me-
tastases only, statistically significant differences in favor of
combination therapy were seen for the objective response rate,
time to disease progression, and survival. Furthermore, prelimi-
nary results of a recent meta-analysis (42) of 506 patients treated
in four randomized trials (including this study) showed that, for
all three efficacy parameters (i.e., response rate, progression-free
survival, and overall survival), combined treatment with an
LHRH agonist plus tamoxifen was superior to treatment with an
LHRH agonist alone. Unfortunately, a meta-analysis on com-
parisons between a combined-treatment arm and treatment with
tamoxifen alone is not possible because of the lack of such
studies.
In our study, there appeared to be no interaction between
clinical prognostic factors and treatment. In unselected patients
with visceral disease, endocrine treatment is generally less ef-
fective, which, however, is mainly due to the association with
negative steroid receptor status (43). Probably because we ex-
cluded steroid receptor-negative patients, visceral metastasis
was not an important prognostic factor for progression-free sur-
vival and overall survival, but a relative high overall response
rate of 39% for all treatment groups together was found (even
about 60% during combined treatment).
The overall survival of patients with metastatic breast cancer
is commonly comparable for combined endocrine treatment and
sequential treatment (9,10). In our study, we did not include a
mandatory crossover for the single-treatment groups because
crossover studies are difficult to conduct well (19). The highly
heterogeneous conditions of individual patients during the
course of metastatic disease require various treatment ap-
proaches. However, we believe that there should be no major
difference among the three arms of our study with regard to
subsequent treatment regimens because the patients were ran-
domly assigned according to individual center and were treated
during the same study period with the same type of chemothera-
peutic and endocrine agents. Thus, the most striking observation
in our study is the highly statistically significant improvement in
overall survival of patients receiving the combination treatment.
This improvement could be the result of a higher response rate
and longer progression-free survival after reduction to a substan-
tially lower tumor load. The greater reduction in tumor load
might have increased the sensitivity of the tumor to other types
of subsequent treatment because of the general relationship be-
tween tumor load and resistance to treatment. Thus, our unex-
pected observation that patients receiving the combined first-line
endocrine treatment tended to survive longer after disease pro-
gression (Fig. 3) is important—this in spite of the fact that fewer
optional endocrine treatments were available for this group from
the time of detection of progressive disease during first-line
endocrine therapy.
Fig. 4. Mean plasma estradiol levels before and during therapy with the three
treatment regimens (see Table 4 for numbers of patients, median and mean
values, and ranges). LHRH-A 4 luteinizing hormone-releasing hormone agonist
(i.e., buserelin); TAM 4 tamoxifen; E2 4 estradiol.
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The results of our study may also aid in the interpretation of
results from published and ongoing (adjuvant) studies on stan-
dard-dose and high-dose chemotherapy. Adjuvant chemotherapy
is more effective in premenopausal women than in postmeno-
pausal women (44), and this effect is positively associated with
chemotherapeutically induced castration in nearly all trials (45–
49). Ablation of functioning ovaries and combination chemo-
therapy with cyclophosphamide, methotrexate, and 5-fluoroura-
cil (CMF) have similar effects on disease-free survival and
overall survival (50). High-dose chemotherapy induces chemical
castration in nearly 100% of the patients, in contrast to standard-
dose chemotherapy, and high-dose chemotherapy is followed by
adjuvant tamoxifen therapy in nearly all trials. Thus, the com-
bination of high-dose chemotherapy and tamoxifen can also in-
directly result in “complete estrogen blockade” in (nearly) all
patients, in contrast to standard treatment (51). Consequently, a
small difference in survival in favor of high-dose chemotherapy
can (at least partly) be explained by differences in indirect en-
docrine effects. This hypothesis is supported by the results of
two randomized trials that show that adjuvant endocrine therapy,
consisting of surgical or medical castration and treatment with
tamoxifen, was statistically significantly superior to standard
chemotherapy with FAC (5-fluorouracil, doxorubicin [i.e.,
Adriamycin], and cyclophosphamide) (52) or CMF (49), al-
though preliminary results of a third adjuvant study (53) did not
reveal a difference between the results of treatment with CMF
and the results of treatment with the LHRH agonist goserelin and
tamoxifen. Recently, in addition to combination chemotherapy
with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF),
combined treatment with goserelin and tamoxifen was shown to
statistically significantly improve the disease-free survival (from
67% to 78%), but treatment with goserelin alone did not (54).
Therefore, it is important to determine whether the additional
beneficial effect of combined endocrine therapy was reached,
especially in women without chemotherapy-induced castration.
In conclusion, our unique three-arm, randomized study
clearly showed that combined treatment with an LHRH agonist
plus tamoxifen is superior to treatment with each drug alone,
with respect to response rate, progression-free survival, and
overall survival among premenopausal patients with metastatic
breast cancer. Therefore, the results of our study are important
for daily standard clinical practice, not only for patients with
metastatic disease but also for patients with steroid receptor-
positive primary tumors. We suggest that future studies also add
aromatase inhibitors to the combined-treatment regimen; this
treatment should further suppress plasma estradiol levels
(55,56).
APPENDIX
Other participating members of the European Organization for Re-
search and Treatment of Cancer (EORTC) Breast Cancer Cooperative
Group are as follows: R. Sylvester/EORTC Data Center, Brussels, Bel-
gium; M. Namer, Centre Antoine Lacassagne, Nice, France; J. P. Julien,
Centre Henri Becquerel, Rouen, France; J. Garcia Conde, Hospital
Clinico Universitario, Valencia, Spain; M. Du¨nser and R. Margreiter,
University Hospital, Innsbruck, Austria; T. Tjabbes, Sophia Hospital,
Zwolle, The Netherlands; K. J. Roozendaal, Onze Lieve Vrouwe Gas-
thuis, Amsterdam, The Netherlands; P. C. van der Velden, Stichting het
van Weel-Bethesda Hospital, Dirksland, The Netherlands; J. W. R.
Nortier, Diakonessenhuis, Utrecht, The Netherlands.
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